SS&C Raises $1.2 Billion In Convertible Debt To Refinance Notes Due In 2027

The financing also funded approximately $100 million in share buybacks and $112.8 million in contracts to limit conversion costs.

Share
SS&C Raises $1.2 Billion In Convertible Debt To Refinance Notes Due In 2027

SS&C Technologies, which provides software and outsourced operations for financial-services and healthcare clients, completed a $1.2 billion convertible-debt sale Friday to help refinance $2 billion of notes due in 2027. An SEC filing Monday confirmed the financing, which also funded share repurchases and contracts intended to limit the cost of future conversions.

A Bigger Refinancing Package

The new notes pay 2.75% annual interest and mature on December 1, 2031, unless converted, redeemed or repurchased sooner. SS&C plans to combine the remaining offering proceeds with bank borrowing to retire $2 billion of existing notes paying 5.500%, which mature on September 30, 2027.

The completed sale included purchasers exercising their entire $150 million option. SS&C's Wednesday announcement proposed a $1 billion offering; Thursday's pricing release set the base at $1.05 billion.

Its subsidiary also borrowed $750 million through Term B loans and $240 million through Term A loans Friday, and added $400 million in revolving-credit commitments. The original proposal called for up to $500 million of additional Term B borrowing.

The Term B loans mature on May 9, 2031. The Term A loans and revolving facility have a November 6, 2031 maturity, but an earlier deadline applies if more than $250 million of Term B loans remain outstanding 91 days before those loans mature.

Buybacks Now, Conversion Costs Later

SS&C received approximately $1.176 billion after the purchasers' discount, before estimated offering expenses. It spent approximately $100 million to buy approximately 1.3 million shares at $79.57 each—the stock's Wednesday closing price—with settlement Friday.

The notes can initially convert at approximately $99.46 per share, about 25% above Wednesday's $79.57 close. SS&C decides whether to meet conversions with cash, stock or a mixture; the initial conversion rate corresponds to 12,064,800 shares, with a maximum of 15,081,000 shares in limited circumstances.

SS&C spent $112.8 million on separate options contracts that it expects to reduce potential dilution or offset conversion payments above the notes' principal. That protection has an initial cap of approximately $139.25 per share, about 75% above Wednesday's closing price. The contracts do not alter noteholders' conversion rights.

Software And Outsourced Financial Operations

SS&C's business spans fund administration for hedge funds, private equity and other asset managers, mutual-fund transfer services and secure virtual data rooms used in deals. SS&C Health processes pharmacy and medical claims for health plans and pharmacy benefit managers.

Outsourced services operated on SS&C's own software supply its main revenue stream, with contracts generally lasting one to five years, alongside software licenses and maintenance. In 2025, US clients accounted for 67% of revenue.

The financing and buybacks are complete; SS&C still plans to redeem the $2 billion of notes due in 2027.

Sources

More on SS&C Technologies

All SS&C Technologies (SSNC) coverage →